The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Protect Your Eyesight
Talking to your eye doctor about risk factors or trouble seeing at night may help detect macular degeneration early enough to delay or prevent blindness.
Breakthrough Technology Meets High-Touch Patient Care
The advanced technology of the AdaptDx Pro™ can help you detect AMD at the subclinical stage and manage this progressive disease to prevent unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instruction every time.
Latest News & Upcoming EventsView More
If you want to help identify AMD patients sooner so that management can begin before substantial vision loss occurs, a new product from Maculogix aims to help.
MacuLogix, Inc. announces the next generation of dark adaptation functional testing with the introduction of the AdaptDx Pro guided by Theia.
How at-home genetic testing has affected AMD patient encounters with eye care practitioners. By Dr. Damon Dierker, OD, FAAO and Dr. Scott Schachter, OD.